Merck and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab

• Merck and Pfizer collaborate with Dako in developing an immunohistochemistry (IHC)-based companion diagnostic (CDx) in immuno-oncology

Darmstadt, Germany, and New York, U.S., September 24, 2015 – As part of the global strategic alliance between Merck and Pfizer to jointly develop and commercialize avelumab*, an investigational immune checkpoint inhibitor, the companies have announced today that they have a collaboration agreement in place with Dako, an Agilent Technologies company, for the development of a potential companion diagnostic test (CDx).

The complete Merck News Release can be downloaded at the following link:
http://news.merck.de/N/0/B736E6FBE0045CAEC1257ECA004F418C/$File/Alliance_DAKO_Eng.pdf